Heart failure treatment equipment based on ultrasonic super lens

Abstract

The invention provides a heart failure treatment device based on an ultrasonic super lens, which comprises a transmitting module and a phase modulation module, the transmitting module comprises a transducer, the phase modulation module comprises the ultrasonic super lens, the transducer and the ultrasonic super lens are tightly attached, the central points of the transducer and the ultrasonic super lens are aligned, and the transducer can transmit a plane wave signal to be modulated. The ultrasonic super lens modulates a plane wave sound field to form a non-diffractive symmetrical Airy sound beam, and generates a focused ultrasonic field at a sub-wavelength focus. Ultrasonic waves are accurately focused on the left ventricle, so that accidental injuries to surrounding sensitive tissues are reduced to the maximum extent, the off-target effect is reduced, and accurate treatment can be achieved without other invasive or complex means. The traditional Chinese medicine composition can effectively reduce myocardial fibrosis and improve cardiac functions, and does not need invasive surgery. In addition, the risk of arrhythmia can be reduced, and long-term and safe heart treatment is achieved.

Description

Technical Field

[0001] The present invention belongs to the technical field of medical devices, and in particular relates to a heart failure treatment device based on an ultrasonic superlens. Background Art

[0002] Heart failure is a complex clinical syndrome characterized by the inability of the heart to pump enough blood to meet the body's metabolic needs, posing a major challenge to global health. Heart failure is mainly caused by left ventricular dysfunction, usually caused by coronary artery disease, hypertension or cardiomyopathy. Despite certain advances in drug therapy, device therapy and surgical intervention, the treatment of heart failure remains challenging due to limited long-term efficacy, side effects and invasiveness of treatment. Ultrasound technology has become a promising way to treat cardiovascular diseases due to its non-invasiveness, real-time imaging capability, low cost and safety. In particular, low-intensity pulsed ultrasound has shown certain therapeutic effects in alleviating myocardial infarction, myocardial fibrosis, viral myocarditis and drug-induced cardiotoxicity. However, traditional ultrasound technology has some limitations, such as low penetration and accidental damage to adjacent tissues. In addition, the complex biological environment (such as the chest cavity and dynamic blood flow) complicates ultrasound propagation, resulting in energy attenuation and wavefront distortion. Summary of the invention

[0003] To solve the above problems, the purpose of the present invention is to provide a heart failure treatment device based on an ultrasonic superlens, which innovatively improves the accuracy and safety of heart failure treatment by combining superlens technology with the non-diffraction and self-healing properties of the Airy ultrasound beam, while reducing the risk of accidental damage to adjacent tissues.

[0004] To achieve the above-mentioned purpose, the technical solution of the present invention is to provide a heart failure treatment device based on an ultrasonic superlens, which includes a transmitting module and a phase modulation module. The transmitting module includes a transducer, and the phase modulation module includes an ultrasonic superlens. The transducer is tightly fitted to the ultrasonic superlens and the center points are aligned. The transducer can transmit a plane wave signal to be modulated, and the ultrasonic superlens modulates the plane wave sound field to form a non-diffracting, symmetrical Airy beam, and generates a focused ultrasonic field at a subwavelength focus.

[0005] The present invention can use the ultrasonic superlens to modulate the plane wave sound field to form a non-diffracting, symmetrical Airy beam that can penetrate obstacles such as ribs, and produce a high-intensity focused sound field with sub-wavelength precision at a specific focal length. Non-diffracting means that even in a complex biological tissue environment, when potential obstacles such as ribs exist, the Airy beam emitted by the focusing superlens can effectively bypass the obstacles without losing its energy and focusing accuracy.

[0006] On the basis of the above scheme, the ultrasonic superlens is composed of concentric rings of different thicknesses with different radii. Different resin thicknesses at different positions are calculated according to the required phase of the Airy beam and the lens material parameters, and the emitted plane acoustic wave is modulated. The phase modulation formula is as follows: in is an exponential decay factor to ensure that the wave transfers finite energy, λ is the ultrasonic wavelength, Ai(.) represents the Airy function, r is the radial coordinate of concentric rings of different thicknesses, r 0 is the initial radius of the central main ring, w is the scale factor.

[0007] The present invention uses the patient's ribs and sternum as reference objects for positioning, and realizes non-invasive in vitro positioning and focusing through calculation, obtaining a sub-wavelength high-precision focus that can resist interference from ribs or other obstacles on the propagation path. Precise treatment can be achieved without other invasive or complex means, thereby ensuring the effectiveness and accuracy of the treatment.

[0008] The present invention is placed at an appropriate position outside the body to accurately locate and focus on the patient's left ventricle, and a medical ultrasonic coupling agent is applied to the position where the ultrasonic superlens contacts the patient's skin. After the sound wave is emitted by the transmitting module, the phase of different positions is modulated by the ultrasonic superlens to construct the required symmetrical Airy beam to form a focused ultrasonic field, thereby generating a sub-wavelength focus of a certain intensity to treat heart failure.

[0009] Preferably, the ultrasonic superlens is made of flexible resin.

[0010] Based on the above scheme, the transmitting module also includes a signal generator and a power amplifier. The signal generator outputs a driving signal, and the driving signal is amplified by the power amplifier and transmitted to the transducer to control the transducer to transmit the plane wave signal to be modulated.

[0011] The signal with the required intensity for treatment is transmitted through the transmitting module and modulated by the ultrasonic superlens to form a symmetrical Airy beam to achieve a sub-wavelength focus in the target area. Preferably, the driving signal of the transmitting module can generate a -6dB focal sound intensity at the sub-wavelength focus after amplitude modulation and duty cycle change.

[0012] Beneficial effects of the present invention: 1. The present invention uses an ultrasonic superlens to precisely modulate a plane wave into a symmetrical Airy beam, which can form a focused acoustic field of a certain intensity at a subwavelength level at a specific focal length, thereby ensuring that the acoustic energy is highly concentrated in a small area of ​​the left ventricle. Precise focusing reduces energy divergence, improves the efficiency and effect of treatment, and reduces the potential impact on surrounding healthy tissues and reduces off-target effects.

[0013] 2. The present invention can be applied to non-invasive in vitro positioning and focusing technology, allowing precise treatment of the heart under non-invasive conditions. By adjusting the position of the ultrasonic superlens in vitro to accurately align the left ventricle, it not only reduces the invasiveness of the treatment process, but also reduces the risk of infection.

[0014] 3. The present invention utilizes the self-repairing property of the Airy acoustic beam, which can effectively penetrate complex media. Under the interference of acoustic waves caused by ribs or other structures, it can maintain the focusing and intensity of the therapeutic focal sound waves, achieve precise treatment of deep tissues, make the treatment process more flexible and effective, and avoid damage to adjacent healthy tissues while maintaining the treatment depth and accuracy.

[0015] 4. The treatment method of the present invention can flexibly adjust the parameters of the ultrasonic superlens, such as focal length and sound beam shape, according to treatment needs to adapt to treatment targets of different sizes and positions, thereby enhancing the adaptability and flexibility of the treatment. By adjusting the parameters, the treatment plan can be optimized to provide customized treatment for specific pathological conditions, thereby improving the overall success rate and efficiency of the treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] The specific embodiments of the present invention are further described in detail below with reference to the accompanying drawings, wherein: Figure 1 This is a schematic diagram of the system structure of the present invention in a mouse experiment; Figure 2 The present invention is based on simulation experiments and Figure 1 Diagram of the sound field during the experiment. DETAILED DESCRIPTION

[0017] The present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments. The advantages and features of the present invention will become more apparent from the following description and claims. It should be noted that the drawings are all in a very simplified form and use non-precise ratios, which are only used to conveniently and clearly assist in explaining the purpose of the embodiments of the present invention.

[0018] It should be noted that all directional indications in the embodiments of the present invention (such as up, down, left, right, front, back, etc.) are only used to explain the relative position relationship, movement status, etc. between the components under a certain specific posture (as shown in the accompanying drawings). If the specific posture changes, the directional indication will also change accordingly.

[0019] like Figure 1 As shown, this embodiment provides a heart failure treatment device based on an ultrasonic superlens, which includes a transmitting module and a phase modulation module. The transmitting module includes a transducer, a signal generator and a power amplifier. The signal generator outputs a driving signal, and the driving signal is amplified by the power amplifier and transmitted to the transducer to control the transducer to transmit a plane wave signal to be modulated. The phase modulation module includes an ultrasonic superlens, which is composed of concentric flexible resin rings of different thicknesses with different radii. Different resin thicknesses at different positions are calculated according to the required phase of the Airy beam and the lens material parameters, and the emitted plane sound wave is modulated. The phase modulation formula is as follows: in is an exponential decay factor to ensure that the wave transfers finite energy, λ is the ultrasonic wavelength, Ai(.) represents the Airy function, r is the radial coordinate of concentric rings of different thicknesses, r 0 is the initial radius of the central main ring, w is the scale factor; The transducer is tightly fitted to the ultrasonic superlens and the center points are aligned. The ultrasonic superlens modulates the plane wave acoustic field to form a non-diffracting, symmetrical Airy acoustic beam and generates a focused ultrasonic field at a subwavelength focus.

[0020] This embodiment constructs a non-diffraction ultrasonic focused sound field based on Airy beam to concentrate the ultrasonic energy transmitted through the ribs at the subwavelength focus in the target area, thereby greatly reducing the influence of the ribs on the propagation of the ultrasonic field. By designing the amplitude and duty cycle of the transmitted signal and modulating the sound intensity at the focus, the safe sound intensity required for the treatment of heart failure is achieved.

[0021] In this embodiment, the placement position of the transmitting module and the ultrasonic superlens outside the mouse body is determined by means of a mouse atlas and in vitro positioning. After the plane wave sound field is modulated by the ultrasonic superlens, a symmetrical Airy beam focusing sound field is formed, which can pass through the mouse chest cavity without diffraction and accurately focus on treating the left ventricle of the mouse, thereby achieving non-invasive and safe precise focusing treatment of the left ventricle.

[0022] For the doxorubicin-induced mouse heart failure animal model, an Airy beam-based ultrasound transmitter was placed at the treatment site on the outside of the mouse chest skin, and a sufficient amount of medical ultrasound coupling agent was applied to the contact position, and low-intensity focused ultrasound treatment was performed for 15 minutes at a fixed time every day.

[0023] After the treatment was completed, the mice were subjected to ultrasound examination, serum index analysis, and heart tissue section staining, proving that the ultrasound superlens-based treatment method for heart failure in mice can achieve the goal of treating heart failure.

[0024] In order to verify the effect of ultrasonic superlens-based treatment of heart failure in mice on cardiac electrical activity, electrocardiogram data during treatment were collected and the variance of RR intervals was analyzed, which proved that the treatment method had little effect on cardiac electrical activity and had high safety.

[0025] like Figure 2 As shown in FIG. 1 , the focused sound field consistency of the present invention under two different conditions: one is in an unobstructed open field, and the other is when there are ribs blocking the sound wave propagation path. The simulation and experimental results show that the present invention can maintain good focused sound field consistency in both environments.

[0026] This highly consistent focusing effect demonstrates the excellent non-diffraction properties of the present invention. This performance indicates that the ultrasound focusing system can provide reliable and efficient treatment solutions in clinical and research environments, especially when precise focusing on specific biological tissues is required.

[0027] Based on the above experimental results, the present invention can effectively reduce myocardial fibrosis and improve cardiac function without the need for invasive surgery. In addition, the present invention can also reduce the risk of arrhythmia and achieve long-term and safe cardiac treatment. The present invention provides an innovative method for non-invasively and accurately targeting deep tissues and subcostal organs, has broad clinical application prospects, and can reduce the complexity of treatment while improving the efficiency and safety of cardiac treatment.

[0028] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Even if various changes are made to the present invention, if these changes fall within the scope of the claims of the present invention and their equivalents, they still fall within the protection scope of the present invention.

Claims

1. A heart failure treatment device based on an ultrasonic superlens, characterized in that: It includes a transmitting module and a phase modulation module. The transmitting module includes a transducer. The phase modulation module includes an ultrasonic superlens. The transducer is tightly fitted to the ultrasonic superlens and the center points are aligned. The transducer can transmit a plane wave signal to be modulated. The ultrasonic superlens modulates the plane wave sound field to form a non-diffraction symmetrical Airy sound beam and generates a focused ultrasonic field at a sub-wavelength focus.

2. The heart failure treatment device based on ultrasonic superlens according to claim 1, characterized in that: The ultrasonic superlens is composed of concentric rings of different thicknesses with different radii. Different resin thicknesses at different positions are calculated according to the required phase of the Airy beam and the lens material parameters, and the emitted plane acoustic wave is modulated. The phase modulation formula is as follows: in is an exponential decay factor to ensure that the wave transfers finite energy, λ is the ultrasonic wavelength, Ai(.) represents the Airy function, r is the radial coordinate of concentric rings of different thicknesses, r 0 is the initial radius of the central main ring, w is the scale factor.

3. The heart failure treatment device based on ultrasonic superlens according to claim 2, characterized in that: The material of the ultrasonic super lens is flexible resin.

4. The heart failure treatment device based on ultrasonic superlens according to any one of claims 1 to 3, characterized in that: The transmitting module also includes a signal generator and a power amplifier. The signal generator outputs a driving signal, and the driving signal is amplified by the power amplifier and then transmitted to the transducer to control the transducer to transmit the plane wave signal to be modulated.

5. The heart failure treatment device based on ultrasonic superlens according to claim 4, characterized in that: The driving signal of the transmitting module can generate a -6dB focal sound intensity at the sub-wavelength focus after amplitude modulation and duty cycle change.

Images